Known targets — ChEMBL curated mechanism
ATP1A1ATP1A2ATP1A3ATP1A4ATP1B1ATP1B2ATP1B3FXYD2
The experimentally established mechanism targets of Digoxin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 known ✓ | P05023 | 15/20 | 1.00 |
| ▸ | ATP1B1 known ✓ | P05026 | 15/20 | 1.00 |
| ▸ | ATP1B2 known ✓ | P14415 | 15/20 | 1.00 |
| ▸ | ATP1A2 known ✓ | P50993 | 15/20 | 1.00 |
| ▸ | ATP1B3 known ✓ | P54709 | 15/20 | 1.00 |
| ▸ | ATP1A3 known ✓ | P13637 | 3/20 | 1.00 |
| ▸ | FXYD2 known ✓ | P54710 | 3/20 | 1.00 |
| ▸ | ATP1A4 known ✓ | Q13733 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | STAT3 | P40763 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | RORC | P51449 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Digoxin SCHEMBL18844792 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL13496262 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| SCHEMBL15497860 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL19998272 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL18594894 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL13322157 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL13496554 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| SCHEMBL15499508 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL22904197 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL18844793 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743573-A1 | DROPLET-BASED SINGLE-CELL JOINT PROFILING OF CHROMATIN TARGETS AND TRANSCRIPTOME | Xie, Yang (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2025014563-A1 | DROPLET-BASED SINGLE-CELL JOINT PROFILING OF CHROMATIN TARGETS AND TRANSCRIPTOME | XIE YANG (US) | 2025-01-16 | — | — | WO | claimed |
| EP-4743573-A1 | DROPLET-BASED SINGLE-CELL JOINT PROFILING OF CHROMATIN TARGETS AND TRANSCRIPTOME | Xie, Yang (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-121574249-A | Anti-CD 45 antibodies and conjugates thereof | VOR生物制药股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| WO-2025014563-A1 | DROPLET-BASED SINGLE-CELL JOINT PROFILING OF CHROMATIN TARGETS AND TRANSCRIPTOME | XIE YANG (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024232599-A1 | NOVEL BENZOTHIOPHENE DERIVATIVE INHIBITING BET PROTEIN AND COMPOSITION FOR TREATMENT OF CANCER, USING SAME | 주식회사 베노바이오 | 2024-11-14 | — | — | WO | disclosed |
| US-20240374628-A1 | Triple Drug Combination (Metformin, Simvastatin, Digoxin) for Targeted Treatment of Colorectal Cancer | WHISPERGENICS, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-117503914-A | Application of pharmaceutical composition in treatment of diabetic nephropathy | 江苏毫末医药生物科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117257789-A | Application of ER beta agonist in preparation of medicines for treating Du's muscular dystrophy | 中国药科大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-109939222-B | Medical application of CREG protein for promoting skeletal muscle regeneration | 中国人民解放军北部战区总医院 | 2023-11-03 | — | — | CN | disclosed |
| US-20230277630-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | AMYLYX PHARMACEUTICALS, INC. | 2023-09-07 | — | — | US | disclosed |
| CN-111655724-A | Treatment of SMC-mediated diseases | 新加坡保健服务私人有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-111630166-A | conditional-siRNA and its use in the treatment of myocardial hypertrophy | 希望之城 | 2020-09-04 | — | — | CN | disclosed |
| CN-106729408-B | Traditional Chinese medicine preparation for treating hysteromyoma and preparation method thereof | 李德鑫 | 2020-05-19 | — | — | CN | disclosed |
| WO-2019190117-A1 | 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 한림제약(주) | 2019-10-03 | — | — | WO | disclosed |
| EP-3458033-A2 | TRIPLE DRUG COMBINATION (METFORMIN, SIMVASTATIN, DIGOXIN) FOR TARGETED TREATMENT OF PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2018044369-A2 | TRIPLE DRUG COMBINATION (METFORMIN, SIMVASTATIN, DIGOXIN) FOR TARGETED TREATMENT OF PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-08 | — | — | WO | disclosed |
| US-9675623-B2 | Non-surgical method of treatment for cataract | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675623-B2 | Non-surgical method of treatment for cataract | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| WO-2016004048-A2 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | BLEND THERAPEUTICS, INC. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277630-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | CYP27A1, SLC10A1, CYP7A1 | ATP1A1 568/4885ATP1B1 297/4885ATP1B2 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.